RSK2, GST-tag Recombinant

Catalog #
40181
$410 *
Size: 10 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human RSK2 (ribosomal S6 kinase 2), full length, with N-terminal GST-tag, expressed by Sf9 insect cells via a baculovirus expression system.

Synonyms
RPS6KA3; HU-3; MAPKAPK1B; CLS; MRX19; ISPK-1; p90-RSK2; pp90RSK2; S6K-alpha3
Product Info
Storage and Usage
Citations
Species
Human
Host Species/Expression System
Sf9 insect cells
Purity
≥90%
Format
Aqueous buffer solution
Formulation
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol.
MW
112 kDa
Amino Acids
full length
Specific Activity
157 pmol/min/µg
Genbank #
NM_004586
UniProt #
P51812
Tag(s)
N-terminal GST-tag
Background
RSK2 is a member of the RSK (ribosomal S6 kinase) family that are growth factor-regulated serine/threonine kinases. RSK2 has been shown to mediate growth factor signaling via RAS and MAPK leading to the induction of CREB serine-133 phosphorylation and activation of gene expression (1). Mutations in RSK2 have been shown to be responsible for Coffin-Lowry syndrome (CLS) which is a X-linked disorder characterized by severe psychomotor retardation, facial and digital dysmorphisms, and progressive skeletal deformations (2).
References
1. Xing, J. et al: Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 1996 Aug 16;273(5277):959-63.
2. Jacquot, S. et al: Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic heterogeneity and a high rate of de novo mutations. Am J Hum Genet. 1998 Dec;63(6):1631-40